Literature DB >> 8372434

Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme.

L Menéndez-Arias1, D Gotte, S Oroszlan.   

Abstract

The Moloney murine leukemia virus (Mo-MuLV) protease has been cloned into the prokaryotic expression vector pGEX-2T, expressed in fusion with the glutathione S-transferase from Schistosoma japonicum, and purified to apparent homogeneity after thrombin cleavage of the chimeric protein. The purified protease showed maximum activity at pH 6.0 and was inhibited by several aspartyl protease inhibitors, found to be active toward the human immunodeficiency virus-1 (HIV-1) protease. Peptides representing maturation cleavage sites in Gag and Gag-Pol polyproteins were accurately cleaved by the recombinant protease, and kinetic parameters have been determined. In addition, oligopeptides mimicking the cleavage site found in the transmembrane protein and leading to the formation of p15E and p2E were also hydrolyzed at the expected position. The Mo-MuLV protease appears to be more closely related to the HIV-1 protease than to the mouse mammary tumor virus enzyme, based on its substrate specificity and sensitivity to aspartyl protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372434     DOI: 10.1006/viro.1993.1511

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  X-ray crystal structure of the N-terminal region of Moloney murine leukemia virus integrase and its implications for viral DNA recognition.

Authors:  Rongjin Guan; Sriram Aiyer; Marie L Cote; Rong Xiao; Mei Jiang; Thomas B Acton; Monica J Roth; Gaetano T Montelione
Journal:  Proteins       Date:  2017-02-03

2.  Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Authors:  Krisztina Matúz; János Mótyán; Mi Li; Alexander Wlodawer; József Tőzsér
Journal:  FEBS J       Date:  2012-08-17       Impact factor: 5.542

3.  Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Authors:  Péter Bagossi; Tamás Sperka; Anita Fehér; János Kádas; Gábor Zahuczky; Gabriella Miklóssy; Péter Boross; József Tözsér
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  HIV protease cleaves poly(A)-binding protein.

Authors:  Enrique Alvarez; Alfredo Castelló; Luis Menéndez-Arias; Luis Carrasco
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.

Authors:  S K Powell; M Artlip; M Kaloss; S Brazinski; R Lyons; G J McGarrity; E Otto
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions.

Authors:  K Inabe; M Nishizawa; S Tajima; K Ikuta; Y Aida
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

8.  Molecular and enzymatic characterization of the porcine endogenous retrovirus protease.

Authors:  Jürgen H Blusch; Sigrid Seelmeir; Klaus von der Helm
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Expression and purification of the mouse mammary tumor virus gag-pro transframe protein p30 and characterization of its dUTPase activity.

Authors:  B Köppe; L Menéndez-Arias; S Oroszlan
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases.

Authors:  Enrique Alvarez; Luis Menéndez-Arias; Luis Carrasco
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.